Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALPL | P05186 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1007015 | 0.90 | MAPK1 (0.61) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| Ethane SCHEMBL6614658 | 0.88 | MAPK1 (0.59) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL31136151 | 0.87 | MAPK1 (0.53) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL12092824 | 0.87 | ALPL (0.54) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL9124815 | 0.83 | MAPK1 (0.49) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL17672394 | 0.81 | MAPK1 (0.79) | MAPK1KMT2AL3MBTL1POLBALPL | |
| SCHEMBL1665229 | 0.81 | DAO (0.58) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL24158019 | 0.80 | MAPK1 (0.46) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL29910402 | 0.80 | KMT2A (0.43) | MAPK1KMT2AL3MBTL1NPSR1POLB | |
| SCHEMBL1423671 | 0.79 | KMT2A (0.54) | MAPK1KMT2AL3MBTL1NPSR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121577799-A | Method for determining 5-acetyl-1H-pyrazole-3-carboxylic acid related substances | 江苏联环药业股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| CN-118546091-A | 5-Acetyl-1H-pyrazole-3-carboxylic acid and preparation method and application thereof | 济南尚博医药股份有限公司 | 2024-08-27 | — | — | CN | disclosed |
| WO-2024152995-A1 | MACROCYCLIC CYCLIN INHIBITORS AS WELL AS PREPARATION METHOD THEREFOR AND USE THEREOF | 上海海量医药科技有限公司 | 2024-07-25 | — | — | WO | disclosed |
| US-11802113-B2 | Substituted pyrazole compounds, compositions containing same, and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2023-10-31 | — | — | US | disclosed |
| US-11802113-B2 | Substituted pyrazole compounds, compositions containing same, and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2023-10-31 | — | — | US | disclosed |
| US-11802113-B2 | Substituted pyrazole compounds, compositions containing same, and use thereof | SHENZHEN TARGETRX, INC. (CN) | 2023-10-31 | — | — | US | disclosed |
| CN-111087324-B | Synthesis method of doramexane | 杭州科巢生物科技有限公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220251046-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-08-11 | — | — | US | disclosed |
| US-20220251046-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2022-08-11 | — | — | US | disclosed |
| CN-111620821-B | Substituted pyrazole compounds, compositions containing the same and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2011-11-10 | — | — | US | disclosed |
| CN-102224142-A | Having a 5-HT2BNovel pyrazole-3-carboxamide derivatives having receptor antagonistic activity | RAQUALIA PHARMA INC | 2011-10-19 | — | — | CN | disclosed |
| US-RE42840-E1 | Stool flushing device | TOTO, LTD. (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2010058858-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | ラクオリア創薬株式会社 (JP) | 2010-05-27 | — | — | WO | disclosed |
| EP-1551403-B1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARM INC (US) | 2009-04-29 | — | — | EP | disclosed |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ARENA PHARMACEUTICALS INC. (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1551403-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | Arena Pharmaceuticals, Inc. (US) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004032928-A1 | 5-SUBSTITUTED 2H-PYRAZONE-3-CARBOXYLIC ACID DERIVATIVES AS ANTILIPOLYTIC AGENTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS SUCH AS DYSLIPIDEMIA | ARENA PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| US-5470862-A | Intravenous anesthetics | OHMEDA PHARMACEUTICAL PRODUCTS DIVISION INC. (US) | 1995-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220251046-A1 | SUBSTITUTED PYRAZOLE COMPOUNDS, COMPOSITIONS CONTAINING SAME, AND USE THEREOF | AR, NR5A1, SRD5A1 | MAPK1 2025/4885KMT2A 2580/4885L3MBTL1 4697/4885 |
| US-20110275628-A1 | NOVEL PYRAZOLE-3-CARBOXAMIDE DERIVATIVE HAVING 5-HT2B RECEPTOR ANTAGONIST ACTIVITY | HTR2B, HTR1B, HTR3B | MAPK1 920/4885KMT2A 2443/4885L3MBTL1 4719/4885 |
| US-20060167270-A1 | 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia | ACE, ACE2, AGTR2 | MAPK1 4056/4885KMT2A 3725/4885L3MBTL1 3985/4885 |
| US-11802113-B2 | Substituted pyrazole compounds, compositions containing same, and use thereof | AR, NR5A1, SRD5A1 | MAPK1 2025/4885KMT2A 2580/4885L3MBTL1 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.